Provided by Tiger Trade Technology Pte. Ltd.

Faeth Therapeutics

36.12
-3.0800-7.86%
Volume:170.52K
Turnover:6.38M
Market Cap:931.13M
PE:-0.25
High:40.17
Open:39.53
Low:35.80
Close:39.20
52wk High:42.14
52wk Low:7.45
Shares:25.78M
Float Shares:811.70K
Volume Ratio:0.53
T/O Rate:21.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-141.6499
EPS(LYR):-16.7239
ROE:-195.26%
ROA:-20.79%
PB:5.38
PE(LYR):-2.16

Loading ...

Faeth Therapeutics Initiated at Buy by TD Cowen

Dow Jones
·
Yesterday

TD Cowen Initiates Coverage on Faeth Therapeutics With Buy Rating

MT Newswires Live
·
Yesterday

Faeth Therapeutics initiated with a Buy at TD Cowen

TIPRANKS
·
Yesterday

Faeth Therapeutics to Host Virtual KOL Event on Endometrial Cancer Multi-Nodal Inhibition

Reuters
·
Sep 08

Faeth Therapeutics Outlines Piktor PI3K-alpha/mTOR Inhibitor Regimen in Corporate Presentation

Reuters
·
Sep 06

Faeth Therapeutics to Present at Upcoming Investor Healthcare Conferences

Reuters
·
Sep 01

Faeth Therapeutics Grants 94,000 Inducement Stock Options at USD 34.52 Per Share

Reuters
·
Aug 28

Faeth Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 28

Needham Initiates Faeth Therapeutics at Buy With $56 Price Target

MT Newswires Live
·
Aug 21

Faeth Therapeutics Initiated at Buy by Needham

Dow Jones
·
Aug 21

Faeth Therapeutics Initiated at Buy on Oral Multi‑Node PI3K/AKT/mTOR Strategy; Analyst Sets $56 Price Target

TIPRANKS
·
Aug 21

U.S. Research Roundup-Health Catalyst, Nektar Therapeutics, TIC Solutions

Reuters
·
Aug 21

U.S. Stocks on the MOVE - Sunrun, JetBlue Airways, Dell Technologies

Reuters
·
Aug 17

Faeth Therapeutics Announces FDA Grant of Fast Track Designation for Piktor Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer

Reuters
·
Aug 17

Faeth Therapeutics - Topline Data from Phase 2 Trial in Advanced Endometrial Cancer Expected by Year-End 2026

THOMSON REUTERS
·
Aug 17

Faeth Therapeutics - Interim Data from Phase 1B/2 Trial in Advanced Breast Cancer Expected in 2027

THOMSON REUTERS
·
Aug 17

Faeth Therapeutics Names Deepak Tiwari SVP of Technical Operations

Reuters
·
Aug 14

Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments

THOMSON REUTERS
·
Aug 14

Faeth Therapeutics Price Target Maintained with a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 11

Faeth Therapeutics Grants New-Hire Stock Options for 11,000 Shares at $25.5 Each

Reuters
·
Aug 08